A novel enzyme immunoassay for plasma thrombospondin: Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo

Thrombosis Research

Volumn 99, Issue 1, 2000, Pages 41-50

  Bergseth, Grethe ^a   Lappegård, Knut T ^b   Videm, Vibeke ^c   Mollnes, Tom E ^a  

^a Dept of Immunol and Transfus Med ^*  (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Beta thromboglobulin; Biocompatibility; Cardiopulmonary bypass; Enzyme immunoassay; Heparin; Platelets; Thrombospondin

Indexed keywords

ADENOSINE; BETA THROMBOGLOBULIN; DIPYRIDAMOLE; HEPARIN; THEOPHYLLINE; THROMBOSPONDIN;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; BLOOD DONOR; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; THROMBOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTICOAGULANTS; BETA-THROMBOGLOBULIN; BIOLOGICAL MARKERS; BLOOD PRESERVATION; CARDIOPULMONARY BYPASS; CITRIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; KINETICS; MALE; PLATELET ACTIVATION; POLYVINYL CHLORIDE; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TEMPERATURE; THROMBOSPONDINS; TIME FACTORS;

EID: 0343603522     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00226-7     Document Type: Article

References (31)

1. Lawler J. The structural and functional properties of thrombospondin. Blood. 67:1986;1197-1209.
2. Mosher D.F. Physiology of thrombospondin. Annu Rev Med. 41:1990;85-97.
3. Frazier W.A. Thrombospondins. Curr Opin Cell Biol. 3:1991;792-799.
4. Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta. 1182:1993;1-14.
5. Legrand C., Dubernard V., RabhiSabile S., daSilva V.M. Functional and clinical significance of thrombospondin. Platelets. 8:1997;211-223.
6. Yamashita Y., Kurohiji T., Tuszynski G.P., Sakai T., Shirakusa T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer. 82:1998;632-638.
7. Nathan F.E., Hernandez E., Dunton C.J., Treat J., Switalska H.I., Joseph R.R., Tuszynski G.P. Plasma thrombospondin levels in patient with gynecologic malignancies. Cancer. 73:1994;2853-2858.
8. Tuszynski G.P., Smith M., Rothman V.L., Capuzzi D.M., Joseph R.R., Katz J., Besa E.C., Treat J., Switalska H.I. Thrombospondin levels in patients with malignancy. Thromb Haemost. 67:1992;607-611.
9. McCrohan M.B., Huang S.W., Sleasman J.W., Klein P.A., Kao K.J. Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis. Thromb Haemost. 58:1987;850-852.
10. French P., McGregor J.L., Berruyer M., Belleville J., Touboul P., Dawes J., Dechavanne M. Comparative evaluation of plasma thrombospondin beta- thromboglobulin and platelet factor 4 in acute myocardial infarction. Thromb Res. 39:1985;619-624.
11. Dawes J., Pratt D.A., Dewar M.S., Preston F.E. Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb Haemost. 59:1988;273-276.
12. Dawes J., Clemetson K.J., Gogstad G.O., Mcgregor J., Clezardin P., Prowse C.V., Pepper D.S. A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb Res. 29:1983;569-581.
13. Switalska H.I., Niewiarowski S., Tuszynski G.P., Rucinski B., Schmaier A.H., Morinelli T.A., Cierniewski C.S. Radioimmunoassay of human platelet thrombospondin. different patterns of thrombospondin and beta-thromboglobulin antigen secretion and clearance from the circulation J Lab Clin Med. 106:1985;690-700.
14. Kao K.J., Klein P.A. A monoclonal antibody-based enzyme-linked immunosorbent assay for quantitation of plasma thrombospondin. Am J Clin Pathol. 86:1986;317-323.
15. Tuszynski G.P., Switalska H.I., Knudsen K. Methods of studying platelet-secreted proteins and the platelet cytoskeleton. Mod Methods Pharmacol. 4:1987;267-286.
16. Kirk G., McLaren M., Belch J.F. Soluble P-selectin assay. importance of correct anticoagulant choice Platelets. 8:1997;159-162.
17. Files J.C., Malpass T.W., Yee E.K., Ritchie J.L., Harker L.A. Studies of human platelet alpha-granule release in vivo. Blood. 58:1981;607-618.
18. Subba Rao P.V., McCartney-Francis N.L., Metcalfe D.D. An avidin-biotin microELISA for rapid measurement of total and allergen-specific human IgE. J Immunol Methods. 57:1983;71-85.
19. Mollnes T.E., Videm V., Christiansen D., Bergseth G., Riesenfeld J., Hovig T. Platelet compatibility of an artificial surface modified with functionally active heparin. Thromb Haemost. 82:1999;1132-1136.
20. Videm V., Mollnes T.E., Fosse E., Mohr B., Bergh K., Hagve T.A., Aasen A.O., Svennevig J.L. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg. 117:1999;794-802.
21. Boscato L.M., Stuart M.C. Incidence and specificity of interference in two-site immunoassays. Clin Chem. 32:1986;1491-1495.
22. Trzeciak M.-C., McGregor J., Renaux J.-L., Ville D., Berruyer M., Dawes J., Dechavanne M. Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. Thromb Res. 40:1985;121-128.
23. Lane D.A., Ireland H., Wolff S., Ranasinghe E., Dawes J. Detection of enhanced in vivo platelet alpha-granule release in different patient groups-comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays. Thromb Haemost. 52:1984;183-187.
24. Gawaz M.P., Ward R.A. Effects of hemodialysis on platelet-derived thrombospondin. Kidney Int. 40:1991;257-265.
25. Bayraktar M., Dundar S., Kirazli S., Teletar F. Platelet factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J Int Med Res. 22:1994;90-94.
26. Cottrell E.D., Kappa J.R., Stenach N., Fisher C.A., Tuszynski G.P., Switalska H.I., Addonizio V.P. Temporary inhibition of platelet function with iloprost (ZK36374) preserves canine platelets during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 96:1988;535-541.
27. Journois D., Mauriat P., Pouard P., Marchot P., Amiral J., Safran D. Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody. J Cardiothorac Vasc Anesth. 8:1994;157-161.
28. Moen O., Fosse E., Brockmeier V., Andersson C., Mollnes T.E., Høgåsen K., Venge P. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. Ann Thorac Surg. 60:1995;1317-1323.
29. Øvrum E., Mollnes T.E., Fosse E., Holen E.A., Tangen G., Abdelnoor M., Ringdal M.L., Øystese R., Venge P. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg. 110:1995;1623-1632.
30. Videm V., Mollnes T.E., Garred P., Svennevig J.L. Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg. 101:1991;654-660.
31. Videm V., Svennevig J.L., Fosse E., Semb G., Østerud B., Mollnes T.E., Nielsen H. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg. 103:1992;806-813.